In patients with chronic non-infectious posterior uveitis RETISERT is designed to deliver corticosteroid therapy for approximately 2.5 years precisely
where it’s needed.
RETISERT (ﬂuocinolone acetonide intravitreal implant) 0.59 mg is a sterile implant designed to release ﬂuocinolone acetonide locally to the posterior segment of the eye at a nominal initial rate of 0.6 μg/day, decreasing over the ﬁrst month to a steady state between 0.3 to 0.4 μg/day over approximately 30 months.
How Supplied: The implant consists of a tablet encased in a silicone elastomer cup containing a release orifice and a polyvinyl alcohol membrane positioned between the tablet and the orifice. The silicone elastomer cup assembly is attached to a silicone elastomer suture tab with silicone adhesive.
Inactive ingredients: Microcrystalline cellulose, polyvinyl alcohol, and magnesium stearate.
Please click here to view the RETISERT full Prescribing Information.
For Information on Reimbursement and Patient Assistance Services, call the FOCUS ON ACCESS
Hotline, (866)-272-8838 (Monday-Friday, 9 AM to 5 PM EST).
Download the Focus on Access Enrollment Form
Indication and Usage
RETISERT (ﬂuocinolone acetonide intravitreal implant) 0.59 mg is a corticosteroid indicated for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye.
Important Safety Information
- Surgical placement of RETISERT (ﬂuocinolone acetonide intravitreal implant) 0.59 mg is contraindicated in active viral, bacterial, mycobacterial or fungal infections of the eye.
- Based on clinical trials with RETISERT, during the 3-year post-implantation period, nearly all phakic eyes are expected to develop cataracts and require cataract surgery.
- As with any surgical procedure, there is risk involved. Potential complications accompanying intraocular surgery to place RETISERT into the vitreous cavity may include, but are not limited to, the following: cataract formation, choroidal detachment, endophthalmitis, hypotony, increased intraocular pressure, exacerbation of intraocular inﬂammation, retinal detachment, vitreous hemorrhage, vitreous loss, and wound dehiscence.
- Following implantation of RETISERT, nearly all patients will experience an immediate and temporary decrease in visual acuity in the implanted eye which lasts for approximately one to four weeks post-operatively.
- Use of corticosteroids may result in elevated IOP and/or glaucoma.Based on clinical trials with RETISERT, within 3 years post-implantation, approximately 77% of patients will require IOP lowering medications to control intraocular pressure and 37% of patients will require ﬁltering procedures to control intraocular pressure.
- Patients should be advised to have ophthalmologic follow-up examinations of both eyes at appropriate intervals following implantation of RETISERT. Physicians should periodically monitor the integrity of the implant by visual inspection.
- Ocular administration of corticosteroids has been associated with delayed wound healing and perforation of the globe where there is thinning of the sclera.
- The most frequently reported ocular adverse events in clinical trials with RETISERT occurring in 50-90% of patients included: cataract, increased intraocular pressure, procedural complications and eye pain. The most common non-ocular event reported was headache (>33%).
RETISERT (ﬂuocinolone acetonide intravitreal implant) 0.59 mg : Additional information